{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T05:35:51Z","timestamp":1736314551908,"version":"3.32.0"},"reference-count":21,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,1,30]],"date-time":"2006-01-30T00:00:00Z","timestamp":1138579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2006,2]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold>Ropivacaine is a relatively new amide\u2010type local anaesthetic, mainly used for surgery and postoperative pain relief. In this study we have investigated the interaction between the CYP3A4 metabolite of ropivacaine, 2\u2032,6\u2032\u2010pipecoloxylidide (PPX), and premedication with, i.e., psychotropic and antianxiety agents (diazepam, midazolam), hypnotics (thiamylal), local anaesthetics (lidocaine), depolarizing muscular relaxants (vecuronium), antihypertensive (clonidine) and H<jats:sub>2<\/jats:sub>\u2010receptor antagonist (cimetidine) using human liver microsomes<jats:italic>in vitro.<\/jats:italic>The effects of the interaction between PPX and premedications were examined using a human liver microsomal preparation<jats:italic>in vitro.<\/jats:italic>The concentrations of ropivacaine and PPX were determined by HPLC with UV detection. The apparent Michaelis\u2010Menten constant (Km) and the maximal velocity of total metabolic formation (V<jats:sub>max<\/jats:sub>) of PPX, the main metabolite of ropivacaine in human liver microsomes, were 17.7 (\u03bcM, mean) and 711 (nmol\/min.\/mg protein, mean), respectively. Five premedications (diazepam, lidocaine, cimetidine, vecuronium and clonidine) did not inhibit ropivacaine metabolism in human liver microsomes at concentrations within the therapeutic range. However, midazolam and thiamylal weakly inhibited ropivacaine metabolism in competitive manner (IC<jats:sub>50<\/jats:sub>7.8 \u03bcM and 250 \u03bcM, respectively). The results show lack of interaction between ropivacaine and seven premedication medicines within the therapeutic range of ropivacaine using human liver microsomes<jats:italic>in vitro<\/jats:italic>.<\/jats:p>","DOI":"10.1111\/j.1742-7843.2006.pto_265.x","type":"journal-article","created":{"date-parts":[[2006,1,30]],"date-time":"2006-01-30T16:10:14Z","timestamp":1138637414000},"page":"181-183","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of Premedication Medicines on the Formation of the CYP3A4\u2010Dependent Metabolite of Ropivacaine, 2\u2032, 6\u2032\u2010Pipecoloxylidide, on Human Liver Microsomes<i>in vitro<\/i>"],"prefix":"10.1111","volume":"98","author":[{"given":"Einosuke","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Inomata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,1,30]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.1988.tb02788.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90131-X"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1993.tb01551.x"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498259009046835"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00679.x"},{"key":"e_1_2_5_7_1","first-page":"955","article-title":"Ropivacaine, a new amide\u2010type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes","volume":"24","author":"Ekstr\u00f6m G.","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_5_8_1","first-page":"962","article-title":"Metabolism and excretion of ropivacaine in humans","volume":"24","author":"Halldin M. M.","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_5_9_1","first-page":"1385","article-title":"Lidocaine metabolism by human cytochrome P\u2010450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P\u2010450s","volume":"255","author":"Imaoka S.","year":"1990","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-200011000-00030"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.2001.880405.x"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0540-8"},{"key":"e_1_2_5_13_1","first-page":"89","article-title":"Oxidation of midazolam and triazolam by human liver cytochrome P450 \u00d8A4","volume":"36","author":"Kronbach T.","year":"1989","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(89)90654-0"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199501000-00026"},{"key":"e_1_2_5_16_1","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3109\/00498259609050260","article-title":"Human liver microsomal diazepam metabolism using cDNA\u2010expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily","volume":"26","author":"Ono S.","year":"1996","journal-title":"Xenobiotica"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2004.00617.x"},{"key":"e_1_2_5_18_1","first-page":"296","article-title":"Effect of phenobarbital on the pharmacokinetics of lidocaine, monoethylglycinexylidide and 3\u2010hydroxylidocaine in the rat: correlation with P450 isoform levels","volume":"25","author":"Nakamoto T.","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-200009000-00045"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0807-3"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1999.tb02009.x"},{"key":"e_1_2_5_22_1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0090-9556(24)15170-7","article-title":"Involvement of CYP1A2 and CYP3A4 in lidocaine N\u2010deethylation and 3\u2010hydroxylation in humans","volume":"28","author":"Wang J. S.","year":"2000","journal-title":"Drug Metab. Dispos."}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-7843.2006.pto_265.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1742-7843.2006.pto_265.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T15:06:39Z","timestamp":1736262399000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-7843.2006.pto_265.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,30]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["10.1111\/j.1742-7843.2006.pto_265.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1742-7843.2006.pto_265.x","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"type":"print","value":"1742-7835"},{"type":"electronic","value":"1742-7843"}],"subject":[],"published":{"date-parts":[[2006,1,30]]},"assertion":[{"value":"2006-01-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}